Abstract
Purpose :
Age-related macular degeneration (AMD) is one of the leading causes of blindness in developed countries, and AMD is reportedly related with oxidative stress. Previously we showed that serum malondialdehyde (MDA), one of the markers of oxidative stress, in patients with wet AMD was significantly higher compared with that without AMD,and that there was a significant correlation between serum MDA levels and choroidal neovascularization lesion size. Diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential（BAP）test are known as markers for evaluating oxidative stress, and, by combining together, they are used for comprehensive evaluation of oxidative stress. In this study, we hypothesized that d-ROMs and BAP tests could be useful markers of AMD.
Methods :
Blood plasma samples from 34 patients with AMD (average age: 76.5±7.7, 22 male and 12 female) and 20 controls subjects(average age: 62.9±14.0, 10 male and 10 female) who visited Nagoya university hospital from 2014 to 2017 were collected and d-ROMs and BAP tests were examined.
Results :
The average value of d-ROMs from male AMD patients and control were 312.0±52.4 U.CARR and 275.1±45.5 U.CARR , respectively, and d-ROMs from male AMD patients was significantly higher than those from male control subjects (p<0.05). Meanwhile, the average value of d-ROMs from female AMD patients and control were 328.6±85.7 U.CARR and 342.5±37.1 U.CARR, respectiely, and d-ROMs from female AMD patients was not significantly difference from those from female control subjects (p=0.16). The average value of BAP from male AMD patients and control were 2241±549μmol/L and 2136±246μmol/L, respectively. The average value of BAP from female AMD patients and control were 2263±292μmol/L and 2335±161μmol/L, respectively. There were no significant differences between AMD group and control group in both males and females.
Conclusions :
D-ROMS can be a useful indicator in male AMD patients. We did not find any significant difference in the BAP values between AMD patients and control subjects.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.